New OIG Special Fraud Alert Focuses on Suspect Practices of Labs and Referring Physicians - Certain Payment Arrangements May Be a Violation of the Federal Medicare/Medicaid Anti-Kickback Statute (AKS)

by Holland & Knight LLP
Contact

HIGHLIGHTS:

  • The U.S. Department of Health and Human Services' Office of Inspector General (OIG) issued a new Special Fraud Alert on June 25, 2014, that focuses on certain compensation arrangements between laboratories and referring physicians.
  • Paying physicians more than fair market value for services, or providing free or below-market goods to referring physicians, could run afoul of the federal Medicare/Medicaid Anti-Kickback Statute (AKS). Both sides of the transaction – physicians and clinical laboratories – could face criminal liability for entering into arrangements that violate the AKS.

The U.S. Department of Health and Human Services' Office of Inspector General (OIG) issued a new Special Fraud Alert on June 25, 2014, that focuses on certain compensation arrangements between laboratories and referring physicians. Since issuing its prior laboratory fraud alert almost 20 years ago, the OIG has emphasized repeatedly that paying physicians more than fair market value for services, or providing free or below-market goods to referring physicians, could run afoul of the federal Medicare/Medicaid Anti-Kickback Statute (AKS).

Claims for laboratory services that result from a violation of the AKS do not meet Medicare's coverage criteria and may constitute false claims under the False Claims Act – even if the services were otherwise medically necessary. The OIG noted that these payment arrangements raise four potential concerns:

  1. corruption of medical judgment
  2. overutilization
  3. increased costs to federal healthcare programs and beneficiaries
  4. unfair competition

This is because making payments that are not commercially reasonable in the absence of referrals, or providing free or below-market goods or services, could induce physicians to choose laboratories, not based on quality or clinical appropriateness, but instead based on which laboratories provide them with remuneration in exchange for the referrals. The OIG observed that these types of arrangements are particularly concerning in the laboratory context because patients have little or no input regarding choosing the entity that will perform the tests. Those decisions are largely controlled by physicians.

Specimen Collection Arrangements

The Special Fraud Alert focuses on two particular types of arrangements. The first involves blood specimen collection, processing and packaging arrangements. Some laboratories pay physicians for specified duties such as blood collection, centrifuging, maintaining the specimens at a particular temperature and packaging them. These payments are often made on a per-patient or per-specimen basis, and often involve expensive tests.

The OIG acknowledged that Medicare allows a small specimen collection fee when a medical professional draws a blood sample through venipuncture. However, this payment is not allowed in all situations. Medicare will pay for this service only when it is the accepted and prevailing practice among physicians in the locality, and the physician performing the services customarily bills separate charges for drawing or collecting the specimen.

Medicare does not allow separate payments for processing and packaging specimens for transport to a laboratory. Instead, these are paid through a bundled code in the Medicare Physician Fee Schedule. When a laboratory pays a physician for these services, the AKS may be violated if there is an intent to reward or induce referrals of federal healthcare program business. Since Medicare is already paying the physician to process and package the specimen, it is more likely that the payment is for an illegitimate purpose.

Specimen processing arrangements that may be unlawful could have various characteristics. For example, payments made directly to the ordering physician, rather than his or her group practice, could be suspect. The OIG stated that payments on a per-specimen basis for more than one specimen collected during a single patient encounter, or a per-patient, per-test or other basis are problematic because they take into account the volume or value of referrals. Additionally, paying the physician for services actually performed by the laboratory's or a third party's phlebotomist could signal an AKS concern.

Some laboratories and physicians attempt to reduce their AKS risks by "carving out" federal healthcare program beneficiaries from these types of questionable arrangements. For example, the physician may receive a payment for patients covered under private insurance, but not Medicare or Medicaid. The Special Fraud Alert makes it clear that these carve-outs can still be problematic. Physicians typically refer to a limited number of laboratories. Therefore, these arrangements can be a disguised way of rewarding Medicare and other federal healthcare program business.

Footnote 5 of the Special Fraud Alert is particularly interesting. The OIG stated that:

The same principles described in this Special Fraud Alert apply to arrangements that are similar or analogous to Specimen Processing Arrangements, including arrangements under which clinical laboratories ... provide free or below-market point of care urine testing cups to health care providers who use the cups to perform billable in-office testing.

Specimen cups are available that provide instant on-site test results for certain drug classes. These cups are much more expensive than the cups that do not provide such test results. For a number of years, laboratories providing the more expensive test cups to physicians at no charge have been a subject of controversy in Florida. In 2008, Florida's Agency for Health Care Administration issued a declaratory statement1 finding that providing physicians with free specimen cups violated agency rules.

Registry Payments

The Special Fraud Alert focuses on a second scenario in which laboratories establish databases purportedly to collect data on patients who have undergone or who may undergo certain tests performed by the offering laboratories. These registry arrangements are referred to using a variety of terms, such as "registries" or "observational outcomes databases." These registry arrangements are supposedly intended to advance clinical research or provide other benefits, but they often involve payments from the laboratories to the physicians for duties such as submitting data, answering patient questions, or reviewing reports.

While the OIG acknowledged that the AKS does not prohibit laboratories from paying compensation for legitimate research activities, the OIG stated that these arrangements may implicate the AKS, depending on the intent of the parties. While payments may be reasonable in certain circumstances, in the OIG's view the AKS prohibits the arrangement if one purpose of the payments is to induce or reward referrals. The Special Fraud Alert provides several examples of characteristics of a registry arrangement that may signal an unlawful purpose, including:

  • requiring physicians to perform tests with a certain frequency in order to receive compensation
  • compensation paid to physicians on a per-patient basis
  • registries that collect data only from the tests performed by a certain laboratory

Implications for Physicians and Laboratories

The OIG noted in the Special Fraud Alert that both sides of the transaction – physicians and clinical laboratories – could face criminal liability for entering into arrangements that violate the AKS. Therefore, it is critical that physicians, as well as laboratories, review their testing relationships carefully to ensure that there is no remuneration in exchange for referrals.

1 In Re: Petition for Declaratory Statement of Dominion Diagnostics, LLC, State of Florida Agency for Health Care Administration, FRAES No. 2008008228 (July 8, 2008).

To ensure compliance with Treasury Regulations (31 CFR Part 10, §10.35), we inform you that any tax advice contained in this correspondence was not intended or written by us to be used, and cannot be used by you or anyone else, for the purpose of avoiding penalties imposed by the Internal Revenue Code.

 

Written by:

Holland & Knight LLP
Contact
more
less

Holland & Knight LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.
Feedback? Tell us what you think of the new jdsupra.com!